Drug: Rinvoq (upadacitinib)

Manufacturer: AbbVie

Route of Administration: Oral

Site of Care: Outpatient

Approved Indication:

• • treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers
  • treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers
  • treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable
  • treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers
  • treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers
  • treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers
  • treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy
  • treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers

Disease: atopic dermatitis, ankylosing spondylitis, Crohn’s disease, juvenile idiopathic arthritis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

Enrollment Form Link: rinvoqhcp.com/resources

Phone Number: N/A

Fax Number: 1-678-727-0690

Product Website: rinvoq.com